2 years and older:
Cream/ointment: Apply a thin layer to the affected area once a day
12 years and older:
Lotion: Apply a thin layer to the affected area once a day
-Safety and efficacy in pediatric patients for more than 3 weeks of use have not been established.
-This topical drug should not be applied in the diaper area if the child still requires diapers or plastic pants.
-Therapy should be discontinued when control is obtained.
-If no improvement is seen within 2 weeks, reassessment of diagnosis may be needed.
Use: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
References: 1. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol . 2006;5(2):125-130. 2. Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol . 2005; 53(1 Suppl 1):s50-s58. 3. US Food and Drug Administration NDA 017765. Promius Pharma, LLC, Princeton, NJ: Aug 1977. 4. Rosenthal AL. Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis . 1980;25(1):96-98. 5. Kircik LH. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay. J Drugs Dermatol . 2014;13(5):582-585. 6. Cloderm [package insert]. Princeton, NJ: Promius Pharma, LLC; 2017.